Physician profile
David Knapp
NPI 1376735613
$1,892.93
in general payments reported to CMS, 2019-2025
20 companies · $60.21 in 2025
The $60.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $294 · 2021: $24.28 · 2022: $335 · 2023: $479 · 2024: $435 · 2025: $60.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.91 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $466.90 | 2022-2024 | Airsupra, Farxiga, Tezspire |
| Boston Scientific Corporation | $249.18 | 2020-2022 | |
| Heartflow, INC. | $247.83 | 2023 | Ffrct |
| Abbott Laboratories | $226.17 | 2020-2024 | Esprit |
| Glaxosmithkline, LLC. | $129.52 | 2019-2024 | Trelegy Ellipta |
| Kestra Medical Technology Services, INC. | $90.00 | 2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $83.82 | 2019 | |
| Pfizer INC. | $66.00 | 2022-2023 | |
| Lilly USA, LLC | $64.43 | 2024-2025 | Mounjaro, Zepbound |
| Scilex Pharmaceuticals INC. | $53.56 | 2019 | |
| Angiodynamics, INC. | $38.17 | 2019 | |
| Astellas Pharma US INC | $27.25 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $24.28 | 2021 | |
| Mylan Specialty L.P. | $23.45 | 2023 | Yupelri |
| Allergan, INC. | $20.68 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.37 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $19.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.21 | 2025 | Zoryve |
| Amgen INC. | $14.16 | 2023 | Otezla, Repatha |
| Radius Health, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.